MAPT and Alzheimer disease: For comparison, the established AD CSF biomarker triad (Aβ42, total-tau and phospho-tau) has very high diagnostic accuracy when evaluated in well-controlled settings, both in cross-sectional studies [45] and in longitudinal studies of early stage patients [46].